abstract: Proliferation of some cultured @entity0 @entity1 cell lines bearing high numbers of @entity7 ( @entity7 ) receptors is paradoxically inhibited by @entity7 in nanomolar concentrations. In the present study, we have investigated the biochemical mechanism of growth inhibition in A431 @entity0 @entity3 cells exposed to exogenous @entity7 . In parallel, we studied a selected subpopulation, @entity10 , which is resistant to @entity7 -mediated growth inhibition. We observed a marked reduction in @entity8 ( @entity8 ) activity when A431 and A431-F cells were cultured with 20 nM @entity7 for 4 h. After further continuous exposure of A431 cells to @entity7 , the @entity8 activity remained at a low level and was accompanied by persistent @entity5 . In contrast, the early reduced @entity8 activity and G1 accumulation in A431-F cells was only transient. We found that, at early time points (4-8 h), @entity7 induces @entity4 / @entity4 mRNA and protein expression in both @entity7 -sensitive A431 cells and @entity7 -resistant A431-F cells. But only in A431 cells, was @entity4 / @entity4 expression sustained at a significantly increased level for up to 5 d after addition of @entity7 . Induction of @entity4 / @entity4 by @entity7 could be inhibited by a specific @entity7 receptor @entity2 kinase inhibitor, @entity9 , suggesting that @entity4 / @entity4 induction was a consequence of receptor @entity2 kinase activation by @entity7 . We also demonstrated that the increased @entity4 / @entity4 was associated with both @entity8 and @entity6 ( @entity6 ). Taken together, our results demonstrate that @entity4 / @entity4 is an important mediator of @entity7 -induced @entity5 and growth inhibition in A431 cells.

title: Prolonged induction of @entity4 / @entity4 / @entity8 / XXXX complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.

answer: @entity6


abstract: @entity8 are currently being tested for the treatment and prevention of several @entity1 @entity2 , including @entity0 . However, the anti- @entity2 and growth inhibitory mechanisms of @entity8 are not well understood. @entity6 (RA) inhibits the growth of the @entity4 receptor-positive (ER+) @entity0 cell line, MCF-7, in a reversible and dose-dependent manner. In contrast, @entity5 , @entity9 ) and insulin are potent stimulators of the proliferation of MCF-7 and several other @entity0 cell lines. Pharmacologic doses of RA (> or = 10(-6) M) completely inhibit @entity5 -stimulated MCF-7 cell growth. Published data suggest that the growth inhibitory action of RA on IGF-stimulated cell growth is linear and dose-dependent, similar to RA inhibition of unstimulated or @entity3 -stimulated MCF-7 cell growth. Surprisingly, we have found that @entity5 or insulin-stimulated cell growth is increased to a maximum of 132% and 127%, respectively, by cotreatment with 10(-7) M RA, and that 10(-9) - 10(-7) M RA increase cell proliferation compared to @entity5 or insulin alone. MCF-7 cells that stably overexpress @entity9 are also resistant to the growth inhibitory effects of 10(-9) - 10(-7) M RA. Treatment with the @entity5 receptor blocking antibody, alpha IR-3, restores RA-induced growth inhibition of @entity5 -treated or @entity9 -overexpressing MCF-7 cells, indicating that the @entity7 is mediating these effects. IGFs cannot reverse all RA effects since the altered cell culture morphology of RA-treated cells is similar in growth-inhibited cultures and in @entity9 expressing clones that are resistant to RA-induced growth inhibition. These results indicate that RA action on MCF-7 cells is biphasic in the presence of @entity5 or insulin with 10(-9) - 10(-7) M RA enhancing cell proliferation and > or = 10(-6) M RA causing growth inhibition. As @entity5 and @entity9 ligands are frequently detectable in @entity0 tissues, their potential for modulation of RA effects should be considered when evaluating @entity8 for use in in vivo experimental studies and for clinical purposes. Additionally, the therapeutic use of inhibitors of IGF action in combination with RA is suggested by these studies.

title: Insulin-like growth factors modulate the growth inhibitory effects of @entity6 on MCF-7 XXXX cells.

answer: @entity0


abstract: @entity8 are currently being tested for the treatment and prevention of several @entity1 @entity2 , including @entity0 . However, the anti- @entity2 and growth inhibitory mechanisms of @entity8 are not well understood. @entity6 (RA) inhibits the growth of the @entity4 receptor-positive (ER+) @entity0 cell line, MCF-7, in a reversible and dose-dependent manner. In contrast, @entity5 , @entity9 ) and insulin are potent stimulators of the proliferation of MCF-7 and several other @entity0 cell lines. Pharmacologic doses of RA (> or = 10(-6) M) completely inhibit @entity5 -stimulated MCF-7 cell growth. Published data suggest that the growth inhibitory action of RA on IGF-stimulated cell growth is linear and dose-dependent, similar to RA inhibition of unstimulated or @entity3 -stimulated MCF-7 cell growth. Surprisingly, we have found that @entity5 or insulin-stimulated cell growth is increased to a maximum of 132% and 127%, respectively, by cotreatment with 10(-7) M RA, and that 10(-9) - 10(-7) M RA increase cell proliferation compared to @entity5 or insulin alone. MCF-7 cells that stably overexpress @entity9 are also resistant to the growth inhibitory effects of 10(-9) - 10(-7) M RA. Treatment with the @entity5 receptor blocking antibody, alpha IR-3, restores RA-induced growth inhibition of @entity5 -treated or @entity9 -overexpressing MCF-7 cells, indicating that the @entity7 is mediating these effects. IGFs cannot reverse all RA effects since the altered cell culture morphology of RA-treated cells is similar in growth-inhibited cultures and in @entity9 expressing clones that are resistant to RA-induced growth inhibition. These results indicate that RA action on MCF-7 cells is biphasic in the presence of @entity5 or insulin with 10(-9) - 10(-7) M RA enhancing cell proliferation and > or = 10(-6) M RA causing growth inhibition. As @entity5 and @entity9 ligands are frequently detectable in @entity0 tissues, their potential for modulation of RA effects should be considered when evaluating @entity8 for use in in vivo experimental studies and for clinical purposes. Additionally, the therapeutic use of inhibitors of IGF action in combination with RA is suggested by these studies.

title: Insulin-like growth factors modulate the growth inhibitory effects of XXXX on MCF-7 @entity0 cells.

answer: @entity6


abstract: UNASSIGNED: We describe a case of @entity5 with massive @entity2 , @entity11 and @entity9 . A 48-year-old @entity0 with parents of a consanguineous marriage, first appeared with decreased urine output, @entity2 on his inner thighs and short stature (142  cm, 47  kg). The @entity0 had suffered from @entity4 since the age of 1  year, and his secondary sexual characteristics had not developed. Computed tomography showed periaortic @entity1 , bilateral @entity8 , @entity10 and @entity7 of the germinal cords. A biopsy from the retroperitoneal mass revealed remarkable @entity1 with chronic inflammatory cells. Biopsies from the @entity2 showed thick collagen bundles through the dermis and lymphohistiocytic infiltration with numerous plasma cells. Serum inflammatory markers, such as C-reactive protein, vascular endothelial factor, transforming growth factor-b and soluble interleukin-2 receptor, were elevated. @entity6 was effective in treating @entity2 and in lowering serum inflammatory markers. After a long period of follow up, genomic DNA of the @entity0 was obtained, and we identified a homozygous mutation in exon 5, @entity14 , which caused transition of @entity12 to @entity3 , @entity15 , in the @entity0 , but not in DNA samples from another 50 healthy individuals. This is the first case of @entity5 with @entity9 and @entity11 , and the first Japanese case of @entity5 reported in the English published work with a novel mutation in the @entity13 gene.

title: Case of @entity5 with massive XXXX , @entity11 and @entity9 with a novel mutation in the @entity13 gene.

answer: @entity2


abstract: UNASSIGNED: We describe a case of @entity5 with massive @entity2 , @entity11 and @entity9 . A 48-year-old @entity0 with parents of a consanguineous marriage, first appeared with decreased urine output, @entity2 on his inner thighs and short stature (142  cm, 47  kg). The @entity0 had suffered from @entity4 since the age of 1  year, and his secondary sexual characteristics had not developed. Computed tomography showed periaortic @entity1 , bilateral @entity8 , @entity10 and @entity7 of the germinal cords. A biopsy from the retroperitoneal mass revealed remarkable @entity1 with chronic inflammatory cells. Biopsies from the @entity2 showed thick collagen bundles through the dermis and lymphohistiocytic infiltration with numerous plasma cells. Serum inflammatory markers, such as C-reactive protein, vascular endothelial factor, transforming growth factor-b and soluble interleukin-2 receptor, were elevated. @entity6 was effective in treating @entity2 and in lowering serum inflammatory markers. After a long period of follow up, genomic DNA of the @entity0 was obtained, and we identified a homozygous mutation in exon 5, @entity14 , which caused transition of @entity12 to @entity3 , @entity15 , in the @entity0 , but not in DNA samples from another 50 healthy individuals. This is the first case of @entity5 with @entity9 and @entity11 , and the first Japanese case of @entity5 reported in the English published work with a novel mutation in the @entity13 gene.

title: Case of @entity5 with massive @entity2 , @entity11 and XXXX with a novel mutation in the @entity13 gene.

answer: @entity9


abstract: UNASSIGNED: We describe a case of @entity5 with massive @entity2 , @entity11 and @entity9 . A 48-year-old @entity0 with parents of a consanguineous marriage, first appeared with decreased urine output, @entity2 on his inner thighs and short stature (142  cm, 47  kg). The @entity0 had suffered from @entity4 since the age of 1  year, and his secondary sexual characteristics had not developed. Computed tomography showed periaortic @entity1 , bilateral @entity8 , @entity10 and @entity7 of the germinal cords. A biopsy from the retroperitoneal mass revealed remarkable @entity1 with chronic inflammatory cells. Biopsies from the @entity2 showed thick collagen bundles through the dermis and lymphohistiocytic infiltration with numerous plasma cells. Serum inflammatory markers, such as C-reactive protein, vascular endothelial factor, transforming growth factor-b and soluble interleukin-2 receptor, were elevated. @entity6 was effective in treating @entity2 and in lowering serum inflammatory markers. After a long period of follow up, genomic DNA of the @entity0 was obtained, and we identified a homozygous mutation in exon 5, @entity14 , which caused transition of @entity12 to @entity3 , @entity15 , in the @entity0 , but not in DNA samples from another 50 healthy individuals. This is the first case of @entity5 with @entity9 and @entity11 , and the first Japanese case of @entity5 reported in the English published work with a novel mutation in the @entity13 gene.

title: Case of @entity5 with massive @entity2 , XXXX and @entity9 with a novel mutation in the @entity13 gene.

answer: @entity11


abstract: UNASSIGNED: We describe a case of @entity5 with massive @entity2 , @entity11 and @entity9 . A 48-year-old @entity0 with parents of a consanguineous marriage, first appeared with decreased urine output, @entity2 on his inner thighs and short stature (142  cm, 47  kg). The @entity0 had suffered from @entity4 since the age of 1  year, and his secondary sexual characteristics had not developed. Computed tomography showed periaortic @entity1 , bilateral @entity8 , @entity10 and @entity7 of the germinal cords. A biopsy from the retroperitoneal mass revealed remarkable @entity1 with chronic inflammatory cells. Biopsies from the @entity2 showed thick collagen bundles through the dermis and lymphohistiocytic infiltration with numerous plasma cells. Serum inflammatory markers, such as C-reactive protein, vascular endothelial factor, transforming growth factor-b and soluble interleukin-2 receptor, were elevated. @entity6 was effective in treating @entity2 and in lowering serum inflammatory markers. After a long period of follow up, genomic DNA of the @entity0 was obtained, and we identified a homozygous mutation in exon 5, @entity14 , which caused transition of @entity12 to @entity3 , @entity15 , in the @entity0 , but not in DNA samples from another 50 healthy individuals. This is the first case of @entity5 with @entity9 and @entity11 , and the first Japanese case of @entity5 reported in the English published work with a novel mutation in the @entity13 gene.

title: Case of @entity5 with massive @entity2 , @entity11 and @entity9 with a novel mutation in the XXXX gene.

answer: @entity13


abstract: UNASSIGNED: We describe a case of @entity5 with massive @entity2 , @entity11 and @entity9 . A 48-year-old @entity0 with parents of a consanguineous marriage, first appeared with decreased urine output, @entity2 on his inner thighs and short stature (142  cm, 47  kg). The @entity0 had suffered from @entity4 since the age of 1  year, and his secondary sexual characteristics had not developed. Computed tomography showed periaortic @entity1 , bilateral @entity8 , @entity10 and @entity7 of the germinal cords. A biopsy from the retroperitoneal mass revealed remarkable @entity1 with chronic inflammatory cells. Biopsies from the @entity2 showed thick collagen bundles through the dermis and lymphohistiocytic infiltration with numerous plasma cells. Serum inflammatory markers, such as C-reactive protein, vascular endothelial factor, transforming growth factor-b and soluble interleukin-2 receptor, were elevated. @entity6 was effective in treating @entity2 and in lowering serum inflammatory markers. After a long period of follow up, genomic DNA of the @entity0 was obtained, and we identified a homozygous mutation in exon 5, @entity14 , which caused transition of @entity12 to @entity3 , @entity15 , in the @entity0 , but not in DNA samples from another 50 healthy individuals. This is the first case of @entity5 with @entity9 and @entity11 , and the first Japanese case of @entity5 reported in the English published work with a novel mutation in the @entity13 gene.

title: Case of XXXX with massive @entity2 , @entity11 and @entity9 with a novel mutation in the @entity13 gene.

answer: @entity5


abstract: The aromatase enzyme complex, which regulates the conversion of @entity8 to @entity7 , may have an important role in regulating @entity4 synthesis in breast tissues. In this study the effect of @entity2 location on aromatase activity in adjacent tissue was examined and related to @entity5 ( @entity5 ) production, which has been shown to stimulate aromatase activity in @entity0 cells. Samples of normal and malignant breast tissues were obtained from 11 @entity1 undergoing mastectomy. In 7 @entity1 , aromatase activity was highest in the quadrant in which the @entity2 was located or on which the @entity2 impinged. Aromatase activity in @entity2 -bearing quadrants was significantly higher than that in adjacent and opposite quadrants. Aromatase activity and @entity5 production, expressed in terms of tissue weight, were significantly higher for @entity2 tissue compared with normal breast adipose tissue. A significant correlation was found between aromatase activity and @entity5 production for @entity0 tissue (rs = 0.56; P < 0.05), but not for adipose tissue from the breast quadrants. Aromatase activity and @entity5 production were also measured in tissue obtained from a normal @entity1 undergoing reduction mammoplasty who had previously had breast augmentation by @entity6 injection, not contained within a capsule. In tissue from this @entity1 there was evidence of @entity3 and a marked macrophage response. Aromatase activity in this tissue was considerably higher than that detected in mastectomy adipose tissue samples, and a significant correlation was found between aromatase activity and @entity5 production (rs = 0.77; P < 0.05). A preliminary study to examine the potential role of cells of the immune system in regulating breast tissue aromatase activity revealed that conditioned medium collected from macrophages and lymphocytes could markedly stimulate aromatase activity in @entity2 -derived fibroblasts. The results of this study confirmed that @entity0 location can influence aromatase activity in adjacent tissues and showed that aromatase activity is increased in @entity2 -bearing quadrants. The increased production of @entity5 by @entity2 tissue and its correlation with aromatase activity suggest that @entity2 may be the major source of @entity5 , which is able to influence aromatase activity in adjacent tissues.

title: Aromatase activity and XXXX production by normal and malignant breast tissues.

answer: @entity5


abstract: To investigate the pathogenicity of T cells infiltrating in the @entity2 , mononuclear cells (MNC), predominantly T cells, isolated from either synovial fluid or synovial tissues of the @entity0 with @entity2 were transferred into @entity3 ( @entity3 ) @entity1 by intraarticular injections. According to our observations in this experimental system, @entity0 with @entity2 could be classified into at least two groups. In one group of @entity0 , the infiltrating MNC induced @entity4 in the recipient @entity3 @entity1 (the positive group). Whereas, in the other group no @entity4 was observed (the negative group). The induction of @entity4 observed in the positive group was prevented by an anti-human @entity5 antibody ( @entity1 ), indicating T cell mediation. Analysis of T cell receptor (TCR) V beta usage by reverse transcriptase polymerase chain reaction in the infiltrating MNC transferred into @entity3 @entity1 revealed a marked skew towards the preferential use of certain V beta genes, which was not seen in the peripheral blood MNC, in only the positive group. The patterns of TCR/V beta skew were not uniform among the @entity0 . The analysis of the PCR-amplified genes of such skewed TCR/ V beta by single strand conformational polymorphism showed distinct bands, indicating that the T cell populations expanding in @entity2 of the positive group were oligoclonal. Furthermore, the enrichment of the T cell populations expressing such skewed TCR/V beta by in vitro stimulation of peripheral blood MNC of the @entity0 with the relevant superantigen enabled the induction of @entity4 in the @entity3 @entity1 . These results suggest that the pathogenic T cells could be activated locally in @entity2 by certain antigens in some, but not in all @entity0 with @entity2 .

title: Transfer of @entity2 into @entity3 @entity1 . The pathogenetic implications of T cell populations oligoclonally expanding in the XXXX .

answer: @entity2


abstract: To investigate the pathogenicity of T cells infiltrating in the @entity2 , mononuclear cells (MNC), predominantly T cells, isolated from either synovial fluid or synovial tissues of the @entity0 with @entity2 were transferred into @entity3 ( @entity3 ) @entity1 by intraarticular injections. According to our observations in this experimental system, @entity0 with @entity2 could be classified into at least two groups. In one group of @entity0 , the infiltrating MNC induced @entity4 in the recipient @entity3 @entity1 (the positive group). Whereas, in the other group no @entity4 was observed (the negative group). The induction of @entity4 observed in the positive group was prevented by an anti-human @entity5 antibody ( @entity1 ), indicating T cell mediation. Analysis of T cell receptor (TCR) V beta usage by reverse transcriptase polymerase chain reaction in the infiltrating MNC transferred into @entity3 @entity1 revealed a marked skew towards the preferential use of certain V beta genes, which was not seen in the peripheral blood MNC, in only the positive group. The patterns of TCR/V beta skew were not uniform among the @entity0 . The analysis of the PCR-amplified genes of such skewed TCR/ V beta by single strand conformational polymorphism showed distinct bands, indicating that the T cell populations expanding in @entity2 of the positive group were oligoclonal. Furthermore, the enrichment of the T cell populations expressing such skewed TCR/V beta by in vitro stimulation of peripheral blood MNC of the @entity0 with the relevant superantigen enabled the induction of @entity4 in the @entity3 @entity1 . These results suggest that the pathogenic T cells could be activated locally in @entity2 by certain antigens in some, but not in all @entity0 with @entity2 .

title: Transfer of XXXX into @entity3 @entity1 . The pathogenetic implications of T cell populations oligoclonally expanding in the @entity2 .

answer: @entity2


abstract: To investigate the pathogenicity of T cells infiltrating in the @entity2 , mononuclear cells (MNC), predominantly T cells, isolated from either synovial fluid or synovial tissues of the @entity0 with @entity2 were transferred into @entity3 ( @entity3 ) @entity1 by intraarticular injections. According to our observations in this experimental system, @entity0 with @entity2 could be classified into at least two groups. In one group of @entity0 , the infiltrating MNC induced @entity4 in the recipient @entity3 @entity1 (the positive group). Whereas, in the other group no @entity4 was observed (the negative group). The induction of @entity4 observed in the positive group was prevented by an anti-human @entity5 antibody ( @entity1 ), indicating T cell mediation. Analysis of T cell receptor (TCR) V beta usage by reverse transcriptase polymerase chain reaction in the infiltrating MNC transferred into @entity3 @entity1 revealed a marked skew towards the preferential use of certain V beta genes, which was not seen in the peripheral blood MNC, in only the positive group. The patterns of TCR/V beta skew were not uniform among the @entity0 . The analysis of the PCR-amplified genes of such skewed TCR/ V beta by single strand conformational polymorphism showed distinct bands, indicating that the T cell populations expanding in @entity2 of the positive group were oligoclonal. Furthermore, the enrichment of the T cell populations expressing such skewed TCR/V beta by in vitro stimulation of peripheral blood MNC of the @entity0 with the relevant superantigen enabled the induction of @entity4 in the @entity3 @entity1 . These results suggest that the pathogenic T cells could be activated locally in @entity2 by certain antigens in some, but not in all @entity0 with @entity2 .

title: Transfer of @entity2 into XXXX @entity1 . The pathogenetic implications of T cell populations oligoclonally expanding in the @entity2 .

answer: @entity3


abstract: To investigate the pathogenicity of T cells infiltrating in the @entity2 , mononuclear cells (MNC), predominantly T cells, isolated from either synovial fluid or synovial tissues of the @entity0 with @entity2 were transferred into @entity3 ( @entity3 ) @entity1 by intraarticular injections. According to our observations in this experimental system, @entity0 with @entity2 could be classified into at least two groups. In one group of @entity0 , the infiltrating MNC induced @entity4 in the recipient @entity3 @entity1 (the positive group). Whereas, in the other group no @entity4 was observed (the negative group). The induction of @entity4 observed in the positive group was prevented by an anti-human @entity5 antibody ( @entity1 ), indicating T cell mediation. Analysis of T cell receptor (TCR) V beta usage by reverse transcriptase polymerase chain reaction in the infiltrating MNC transferred into @entity3 @entity1 revealed a marked skew towards the preferential use of certain V beta genes, which was not seen in the peripheral blood MNC, in only the positive group. The patterns of TCR/V beta skew were not uniform among the @entity0 . The analysis of the PCR-amplified genes of such skewed TCR/ V beta by single strand conformational polymorphism showed distinct bands, indicating that the T cell populations expanding in @entity2 of the positive group were oligoclonal. Furthermore, the enrichment of the T cell populations expressing such skewed TCR/V beta by in vitro stimulation of peripheral blood MNC of the @entity0 with the relevant superantigen enabled the induction of @entity4 in the @entity3 @entity1 . These results suggest that the pathogenic T cells could be activated locally in @entity2 by certain antigens in some, but not in all @entity0 with @entity2 .

title: Transfer of @entity2 into @entity3 XXXX . The pathogenetic implications of T cell populations oligoclonally expanding in the @entity2 .

answer: @entity1


abstract: BACKGROUND: Identification of diseased and normal parathyroid glands during parathyroid surgery can be challenging. The aim of this study was to assess whether near-infrared (NIR) fluorescence imaging using administration of a low-dose @entity4 (MB) at the start of the operation could provide optical guidance during parathyroid surgery and assist in the detection of @entity3 . METHODS: @entity0 diagnosed with @entity1 planned for parathyroidectomy were included. @entity0 received 0.5 mg/kg MB intravenously directly after start of anesthesia. During the operation, NIR fluorescence imaging was performed to identify @entity3 . Imaging results were compared with a previous published feasibility study in which 12 @entity0 received MB after intraoperative identification of the @entity2 . RESULTS: A total of 13 @entity0 were included in the current study. In 10 of 12 @entity0 with a histologically proven @entity2 , the @entity2 was fluorescent. Mean signal to background ratio was 3.1    2.8. Mean diameter of the resected lesions was 17    9 mm (range 5-28 mm). @entity2 could be identified up to 145 minutes after administration, which was the longest timespan until resection. Interestingly, in 3 @entity0 , a total of 6 normal parathyroid glands (median diameter 2.5 mm) with a signal to background ratio of 1.8    0.4 were identified using NIR fluorescence imaging. CONCLUSION: Early administration of low-dose MB provided guidance during parathyroidectomy by identifying both @entity3 and normal parathyroid glands. In @entity0 in whom difficult identification of the @entity3 is expected or when normal glands have to be identified, the administration of MB may improve surgical outcome.

title: Intraoperative guidance in parathyroid surgery using near-infrared fluorescence imaging and low-dose XXXX .

answer: @entity4


abstract: The aim of the present retrospective study was to determine the long-term quality of life of @entity0 who had undergone @entity1 resection. 135 @entity0 with a @entity1 located in the floor of the mouth and the adjacent area were enrolled in the study. A standard questionnaire was used to determine the physical functional status, the psychological status and social functioning of @entity1 @entity0 (Schipper et al., 1984). The results were related to the T-stage, the size and the location of the intraoral soft tissue defect, the mode of reconstruction and the postoperative interval. The results showed a significant correlation of the Functional Living Index-Cancer (FLIC) score with the Karnowsky-Index. The values were significantly lower in the higher T-stages. The location of the soft tissue defect, the type of soft tissue reconstruction and discontinuity resections of the mandible were crucial for postoperative quality of life, inasmuch as @entity2 with loss of mandibular continuity and myocutaneous flap reconstructions showed significantly lower FLIC values. Reconstruction of mandibular continuity did not contribute to an increase in FLIC values. @entity4 , reflux of food through the lips and nose during meals, decreased appetite and persistent @entity3 significantly decreased the FLIC scores. It is concluded, that the FLIC is suitable for the determination of life quality in @entity1 @entity0 since the score has shown the potential to reflect differences in postoperative life quality with regard to surgical procedures and functional sequelae.

title: Long-term quality of life after ablative XXXX surgery.

answer: @entity1


abstract: AIM: To establish a cellular model correctly mimicking the gastric epithelium to overcome the limitation in the study of @entity1 ( @entity1 ) infection. METHODS: Aiming to overcome this limitation, clones of the heterogenic cancer-derived @entity0 cell line were isolated, by stably-transducing it with the @entity0 @entity3 (hTERT) catalytic subunit gene. The clones were first characterized regarding their cell growth pattern and phenotype. For that we measured the clones' adherence properties, expression of cell-cell junctions' markers ( @entity10 and @entity8 ) and ability to generate a sustained transepithelial electrical resistance. The gastric properties of the clones, concerning expression of mucins, zymogens and glycan contents, were then evaluated by @entity9 and @entity2 staining, @entity6 Schiff (PAS) and PAS/Alcian Blue-staining, immunocytochemistry and Western blot. In addition, we assessed the usefulness of the hTERT-expressing gastric cell line for @entity1 research, by performing co-culture assays and measuring the IL-8 secretion, by ELISA, upon infection with two @entity1 strains differing in virulence. RESULTS: Compared with the parental cell line, the most promising NCI-hTERT-derived clones (CL5 and @entity14 ) were composed of cells with homogenous phenotype, presented higher relative telomerase activities, better adhesion properties, ability to be maintained in culture for longer periods after confluency, and were more efficient in PAS-reactive mucins secretion. Both clones were shown to produce high amounts of @entity4 , @entity5 and @entity15 . NCI-hTERT-CL5 mucins were shown to be decorated with blood group @entity11 (BG-H), Lewis-x ( @entity7 ), @entity13 and Le(a) and, in a less extent, with BG-A antigens, but the former two antigens were not detected in the NCI-hTERT- @entity14 . None of the clones exhibited detectable levels of @entity12 nor sialylated @entity7 and Le(a) glycans. Entailing good gastric properties, both NCI-hTERT-clones were found to produce @entity16 and @entity0 @entity17 . The progenitor-like phenotype of NCI-hTERT- @entity14 cells was highlighted by large nuclei and by the apical vesicular-like distribution of mucin 5AC and @entity16 , supporting the accumulation of mucus-secreting and zymogens-chief mature cells functions. CONCLUSION: These traits, in addition to resistance to microaerobic conditions and good responsiveness to @entity1 co-culture, in a strain virulence-dependent manner, make the NCI-hTERT- @entity14 a promising model for future in vitro studies.

title: New NCI-N87-derived XXXX gastric epithelial line after @entity0 telomerase catalytic subunit over-expression.

answer: @entity0


abstract: AIM: To establish a cellular model correctly mimicking the gastric epithelium to overcome the limitation in the study of @entity1 ( @entity1 ) infection. METHODS: Aiming to overcome this limitation, clones of the heterogenic cancer-derived @entity0 cell line were isolated, by stably-transducing it with the @entity0 @entity3 (hTERT) catalytic subunit gene. The clones were first characterized regarding their cell growth pattern and phenotype. For that we measured the clones' adherence properties, expression of cell-cell junctions' markers ( @entity10 and @entity8 ) and ability to generate a sustained transepithelial electrical resistance. The gastric properties of the clones, concerning expression of mucins, zymogens and glycan contents, were then evaluated by @entity9 and @entity2 staining, @entity6 Schiff (PAS) and PAS/Alcian Blue-staining, immunocytochemistry and Western blot. In addition, we assessed the usefulness of the hTERT-expressing gastric cell line for @entity1 research, by performing co-culture assays and measuring the IL-8 secretion, by ELISA, upon infection with two @entity1 strains differing in virulence. RESULTS: Compared with the parental cell line, the most promising NCI-hTERT-derived clones (CL5 and @entity14 ) were composed of cells with homogenous phenotype, presented higher relative telomerase activities, better adhesion properties, ability to be maintained in culture for longer periods after confluency, and were more efficient in PAS-reactive mucins secretion. Both clones were shown to produce high amounts of @entity4 , @entity5 and @entity15 . NCI-hTERT-CL5 mucins were shown to be decorated with blood group @entity11 (BG-H), Lewis-x ( @entity7 ), @entity13 and Le(a) and, in a less extent, with BG-A antigens, but the former two antigens were not detected in the NCI-hTERT- @entity14 . None of the clones exhibited detectable levels of @entity12 nor sialylated @entity7 and Le(a) glycans. Entailing good gastric properties, both NCI-hTERT-clones were found to produce @entity16 and @entity0 @entity17 . The progenitor-like phenotype of NCI-hTERT- @entity14 cells was highlighted by large nuclei and by the apical vesicular-like distribution of mucin 5AC and @entity16 , supporting the accumulation of mucus-secreting and zymogens-chief mature cells functions. CONCLUSION: These traits, in addition to resistance to microaerobic conditions and good responsiveness to @entity1 co-culture, in a strain virulence-dependent manner, make the NCI-hTERT- @entity14 a promising model for future in vitro studies.

title: New NCI-N87-derived @entity0 gastric epithelial line after XXXX telomerase catalytic subunit over-expression.

answer: @entity0


abstract: UNASSIGNED: Smartphone applications that record a single-lead ECG are increasingly available. We sought to determine the utility of a smartphone application (AliveCor) to record @entity4 ( @entity4 ) and to distinguish @entity3 ( @entity3 ) from @entity3 ( @entity3 ) in pediatric @entity0 . A prior study demonstrated that interpretation of standard event and Holter monitors accurately identifies the @entity2 mechanism in only 45  % of recordings. We performed an IRB-approved prospective study in pediatric @entity0 undergoing an ablation for @entity4 . Tracings were obtained by placing the smartphone in three different positions on the chest (PI-horizontal, PII-rotated 60   clockwise, and PIII-rotated 120   clockwise). Two blinded pediatric electrophysiologists jointly analyzed a pair of @entity1 and @entity2 tracings in each position. Tracings with visible retrograde P waves were classified as @entity3 . The three positions were compared by Chi-square test. Thirty-seven @entity0 (age 13.7      2.8  years) were enrolled in the study. Twenty-four had @entity3 , and 13 had @entity3 . One hundred and eight pairs of tracings were obtained. The correct diagnosis was made in 27/37 (73  %) with position PI, 28/37 (76  %) with PII, and 20/34 (59  %) with PIII (p  =  0.04 for PII vs. PIII and p  =  NS for other comparisons). A single-lead ECG obtained with a smartphone monitor can successfully record @entity4 in pediatric @entity0 and can predict the @entity4 mechanism at least as well as previously published reports of Holter monitors, along with the added convenience of not requiring @entity0 to carry a dedicated monitor.

title: A Smartphone Application to Diagnose the Mechanism of Pediatric XXXX .

answer: @entity4


abstract: PURPOSE: Available studies of craniocervical junction (CCJ) involvement in @entity2 ( @entity2 ) are based on conventional radiography, which has limited ability in the definition of many elements of the CCJ. The goal of the present study was to describe the spectrum of computed tomography (CT) findings in the CCJ in a cohort of @entity0 with @entity2 . METHODS: CT scans of the cervical spine of 11 @entity0 with @entity2 and 33 control subjects were reviewed, and imaging findings related to the CCJ were assessed. The standard anatomic intervals describing the CCJ were measured and compared to accepted normal standards. Findings representing pathology were described, categorized by localization, and relation to joints or ligaments of the CCJ. RESULTS: All @entity2 @entity0 were males with median age of 48  years and median disease duration of 20  years. The calculated median-modified Stoke @entity2 Spinal Score (mSASSS) for the cervical spine was 8.5 ranging from 0 to 27. Disease-related changes in one or more elements of the CCJ were detected in all @entity0 . @entity3 were involved in 8 @entity0 , while 3 @entity0 had disease of the @entity4 . Enthesopathy of the CCJ was observed in 7 @entity0 . CONCLUSIONS: The CCJ is frequently involved in @entity2 @entity0 with @entity1 and may be independent on the mSASSS. Both articulations and ligaments of CCJ may be affected in @entity2 @entity0 .

title: Craniocervical junction involvement in XXXX .

answer: @entity2


abstract: Introduction. Metabolic conditions, including type 2 @entity1 , have been related to @entity2 ( @entity2 ) risk. We have further analyzed the role of @entity1 and antidiabetic treatments on @entity2 . Methods. Data derived from a hospital-based case-control study (Italy, 2005-2012) on 224 @entity2 @entity0 and 389 controls. Odds ratios (ORs) were estimated using multiple logistic regression models. Results. Sixty-nine (30.9%) cases versus 52 (13.5%) controls reported a @entity1 diagnosis, corresponding to a multivariate OR of 2.25 (95% confidence interval, CI = 1.42-3.56). A stronger excess risk emerged for a longer time since @entity1 diagnosis (OR = 2.96 for <10 years and 5.33 for >= 10 years). Oral therapies were inversely, though not significantly, related to @entity2 risk, OR being 0.44 for @entity4 and 0.88 for @entity5 ; conversely, insulin was nonsignificantly directly associated (OR = 1.90). Compared to nondiabetic subjects who were never smokers, those who were @entity1 and ever smokers had an OR of 6.61 (95% CI 3.31-13.25). Conclusion. Our study confirms an over 2-fold excess @entity2 risk in @entity1 , with a stronger excess risk in @entity1 subjects who are also @entity3 smokers. @entity4 may decrease the risk of @entity2 , whereas insulin may increase the risk.

title: @entity1 and Insulin Therapy, but Not XXXX , Are Related to Hepatocellular Cancer Risk.

answer: @entity4


abstract: Introduction. Metabolic conditions, including type 2 @entity1 , have been related to @entity2 ( @entity2 ) risk. We have further analyzed the role of @entity1 and antidiabetic treatments on @entity2 . Methods. Data derived from a hospital-based case-control study (Italy, 2005-2012) on 224 @entity2 @entity0 and 389 controls. Odds ratios (ORs) were estimated using multiple logistic regression models. Results. Sixty-nine (30.9%) cases versus 52 (13.5%) controls reported a @entity1 diagnosis, corresponding to a multivariate OR of 2.25 (95% confidence interval, CI = 1.42-3.56). A stronger excess risk emerged for a longer time since @entity1 diagnosis (OR = 2.96 for <10 years and 5.33 for >= 10 years). Oral therapies were inversely, though not significantly, related to @entity2 risk, OR being 0.44 for @entity4 and 0.88 for @entity5 ; conversely, insulin was nonsignificantly directly associated (OR = 1.90). Compared to nondiabetic subjects who were never smokers, those who were @entity1 and ever smokers had an OR of 6.61 (95% CI 3.31-13.25). Conclusion. Our study confirms an over 2-fold excess @entity2 risk in @entity1 , with a stronger excess risk in @entity1 subjects who are also @entity3 smokers. @entity4 may decrease the risk of @entity2 , whereas insulin may increase the risk.

title: XXXX and Insulin Therapy, but Not @entity4 , Are Related to Hepatocellular Cancer Risk.

answer: @entity1


abstract: OBJECTIVES: This study assessed the useful role of intracardiac mapping and radiofrequency catheter ablation in eliminating drug-refractory monomorphic @entity4 in severely symptomatic @entity0 . BACKGROUND: @entity4 is commonly encountered in clinical practice. Usually, it is not associated with life-threatening consequences in the absence of significant structural @entity1 . However, frequent @entity4 can be extremely symptomatic and even incapacitating in some @entity0 . Currently, reassurance and pharmacologic therapy are the mainstays of treatment. There has been little information on the use of catheter ablation in such @entity0 . METHODS: Ten @entity0 with frequent and severely symptomatic monomorphic @entity4 were selected from three tertiary care centers. The mean frequency +/- SD of @entity4 was 1,065 +/- 631 beats/h (range 280 to 2,094) as documented by baseline 24-h ambulatory electrocardiographic (ECG) monitoring. No other spontaneous @entity2 were documented. These @entity0 had previously been unable to tolerate or had been unsuccessfully treated with a mean of 5 +/- 3 antiarrhythmic drugs. The site of origin of @entity4 was accurately mapped by using earliest endocardial activation time during ectopic activity or pace mapping, or both. RESULTS: During electrophysiologic study, no @entity0 had inducible @entity3 . The ectopic focus was located in the right ventricular outflow tract in nine @entity0 and in the left ventricular posteroseptal region in one @entity0 . Frequent @entity4 were successfully eliminated by catheter-delivered radiofrequency energy in all 10 @entity0 . The mean number of radiofrequency applications was 2.6 +/- 1.3 (range 1 to 5). No complications were encountered. During a mean follow-up period of 10 +/- 4 months, no @entity0 had a recurrence of symptomatic ectopic activity, and 24-h ambulatory ECG monitoring showed that the frequency of @entity4 was 0 beat/h in seven @entity0 , 1 beat/h in two @entity0 and 2 beats/h in one @entity0 . CONCLUSIONS: Radiofrequency catheter ablation can be successfully used to eliminate monomorphic @entity4 . It may therefore be a reasonable alternative for the treatment of severely symptomatic, drug-resistant monomorphic @entity4 in @entity0 without significant structural @entity1 .

title: Radiofrequency catheter ablation for management of symptomatic XXXX .

answer: @entity4


abstract: Participatory systems for surveillance of acute @entity2 give real-time information about infections circulating in the community, yet to-date are limited to self-reported syndromic information only and lacking methods of linking symptom reports to infection types. We developed the GoViral platform to evaluate  whether a cohort of lay volunteers could, and  would find it  useful to, contribute self-reported symptoms online  and to compare specimen types for self-collected diagnostic information of sufficient quality for @entity2 surveillance. Volunteers were recruited, given a kit (collection materials and customized instructions), instructed to report their symptoms weekly, and when sick with @entity1 , requested to collect specimens (saliva and nasal swab). We compared specimen types for respiratory virus detection sensitivity (via polymerase-chain-reaction) and ease of collection. @entity0 were surveyed to determine receptivity to participating when sick, to receiving information on the type of pathogen causing their infection and types circulating near them. Between December 1 2013 and March 1 2014, 295 @entity0 enrolled in the study and received a kit. Of those who reported symptoms, half (71) collected and sent specimens for analysis. @entity0 submitted kits on average 2.30 days (95 CI: 1.65 to 2.96) after symptoms began. We found good concordance between nasal and saliva specimens for multiple pathogens, with few discrepancies.  Individuals report that saliva collection is easiest and report that receiving information about what pathogen they, and those near them, have is valued and can shape public health behaviors. Community-submitted specimens can be used for the detection of acute @entity2 with individuals showing receptivity for participating and interest in  a real-time picture of respiratory pathogens near them.

title: Surveillance of Acute XXXX Using Community-Submitted Symptoms and Specimens for Molecular Diagnostic Testing.

answer: @entity2


abstract: OBJECTIVES: This study sought to analyze the role of complex lesion morphology on the acute results of angioplasty. BACKGROUND: Acute complications of angioplasty are higher in unstable than in stable @entity4 . The unstable culprit lesion is usually complex, indicative of plaque disruption and @entity3 formation. Previous nonrandomized studies have shown that the presence of intracoronary thombus increases morbidity after coronary angioplasty. The role of complex morphology in coronary angioplasty outcome was studied in a prespecified subgroup analysis of a large multicenter coronary angioplasty trial. METHODS: The results of coronary angioplasty from the Thrombolysis and Angioplasty in @entity7 (TAUSA) trial were analyzed. This large trial randomized 469 @entity0 in double-blinded manner to receive either intracoronary urokinase or placebo during coronary angioplasty of the culprit lesion in @entity1 with or without recent @entity6 . The study presented here analyzes in detail the results of coronary angioplasty in complex versus simple lesions in the urokinase and placebo groups. @entity2 were defined before angioplasty by a core laboratory as having one or more of the following: irregular borders, overhanging edges, @entity5 or intraluminal filling defects proximal or distal to the lesion. RESULTS: Of the 469 @entity0 , 458 had identifiable culprit lesions, of which 245 were complex and 213 were simple. @entity2 were associated with a higher abrupt closure rate than simple lesions (10.6% vs. 3.3%, respectively, p < 0.003). @entity0 with complex lesions also had higher recurrent in-hospital @entity4 (p < 0.02) and emergent bypass surgery (p < 0.02). Further analysis of complex lesions revealed that abrupt closure was particularly high in the urokinase group (15.0% vs 5.9% for the placebo group, p < 0.03), and most abrupt closures were @entity3 . Composite clinical end points were also significantly higher with complex lesions and urokinase. In the placebo group, complex lesions had a higher abrupt closure rate as well as postcoronary angioplasty filling defects, but clinical end points were not significantly different. CONCLUSIONS: @entity2 before coronary angioplasty increase acute complication rates after coronary angioplasty. Urokinase as administered in the TAUSA trial had significant adverse effects, especially in complex lesions. However, even in the placebo arm, complex lesions were associated with higher complication rates than simple lesions. Newer antithrombotic measures that particularly target the platelet may eventually decrease complication rates in these lesions.

title: Angioplasty of complex lesions in XXXX : results of the Thrombolysis and Angioplasty in @entity7 (TAUSA) trial.

answer: @entity1


abstract: OBJECTIVES: This study sought to analyze the role of complex lesion morphology on the acute results of angioplasty. BACKGROUND: Acute complications of angioplasty are higher in unstable than in stable @entity4 . The unstable culprit lesion is usually complex, indicative of plaque disruption and @entity3 formation. Previous nonrandomized studies have shown that the presence of intracoronary thombus increases morbidity after coronary angioplasty. The role of complex morphology in coronary angioplasty outcome was studied in a prespecified subgroup analysis of a large multicenter coronary angioplasty trial. METHODS: The results of coronary angioplasty from the Thrombolysis and Angioplasty in @entity7 (TAUSA) trial were analyzed. This large trial randomized 469 @entity0 in double-blinded manner to receive either intracoronary urokinase or placebo during coronary angioplasty of the culprit lesion in @entity1 with or without recent @entity6 . The study presented here analyzes in detail the results of coronary angioplasty in complex versus simple lesions in the urokinase and placebo groups. @entity2 were defined before angioplasty by a core laboratory as having one or more of the following: irregular borders, overhanging edges, @entity5 or intraluminal filling defects proximal or distal to the lesion. RESULTS: Of the 469 @entity0 , 458 had identifiable culprit lesions, of which 245 were complex and 213 were simple. @entity2 were associated with a higher abrupt closure rate than simple lesions (10.6% vs. 3.3%, respectively, p < 0.003). @entity0 with complex lesions also had higher recurrent in-hospital @entity4 (p < 0.02) and emergent bypass surgery (p < 0.02). Further analysis of complex lesions revealed that abrupt closure was particularly high in the urokinase group (15.0% vs 5.9% for the placebo group, p < 0.03), and most abrupt closures were @entity3 . Composite clinical end points were also significantly higher with complex lesions and urokinase. In the placebo group, complex lesions had a higher abrupt closure rate as well as postcoronary angioplasty filling defects, but clinical end points were not significantly different. CONCLUSIONS: @entity2 before coronary angioplasty increase acute complication rates after coronary angioplasty. Urokinase as administered in the TAUSA trial had significant adverse effects, especially in complex lesions. However, even in the placebo arm, complex lesions were associated with higher complication rates than simple lesions. Newer antithrombotic measures that particularly target the platelet may eventually decrease complication rates in these lesions.

title: Angioplasty of complex lesions in @entity1 : results of the Thrombolysis and Angioplasty in XXXX (TAUSA) trial.

answer: @entity7


abstract: UNASSIGNED: Objective To study the incidence, clinical presentation, risk factors, imaging diagnosis, and clinical outcome of perinatal @entity3 . Methods Data was retrospectively collected from full-term newborns admitted to the neonatal unit of a level III maternity in Lisbon with @entity3 , from January 2007 to December 2011. Results There were 11 cases of @entity3 : nine were arterial @entity5 and two were @entity1 . We estimated an incidence of arterial @entity1 of 7.2/100,000 births. There were two cases of recurrent @entity3 . Eight @entity0 presented with symptoms while the remaining three were asymptomatic and incidentally diagnosed. The most frequently registered symptoms (8/11) were @entity6 ; in that, generalized clonic (3/8) and focal clonic (5/8). @entity3 were more commonly left-sided (9/11), and the most affected artery was the left middle cerebral artery (8/11). Transfontanelle ultrasound was positive in most of the @entity0 (10/11), and @entity3 was confirmed by cerebral magnetic resonance in all @entity0 . Electroencephalographic recordings were carried out in five @entity0 and were abnormal in three (focal abnormalities n=2, burst-suppression pattern n=1). Eight @entity0 had previously identified risk factors for @entity3 which included @entity7 . Ten @entity0 were followed up at outpatients setting; four @entity0 developed @entity2 and one presented with @entity4 . Conclusions Although a modest and heterogeneous sample, this study emphasizes the need for a high level of suspicion when it comes to @entity3 , primarily in the presence of risk factors. The prevalence of neurological sequelae in our series supports the need of long-term follow-up and early intervention strategies.

title: Perinatal XXXX : a five-year retrospective study in a level-III maternity.

answer: @entity5


abstract: Both @entity3 ( @entity3 )A and GABAB receptor subtypes have been implicated in spinally mediated antinociception in @entity8 models. In the current study, the @entity0 test was used as a model of protracted nociception to examine the effect of intrathecally (i.t.) administered @entity5 (GABAB agonist), @entity6 (GABAA agonist) or @entity4 (a @entity2 ) on antinociception. At doses that did not affect motor function, @entity5 (0.3 and 1.0 micrograms, i.t.) decreased the flinch response in a dose-dependent manner during Phase 1 and Phase 2. This effect was reversible by the GABAB-specific antagonist, @entity7 ( @entity7 ). @entity6 (0.3 and 1.0 microgram i.t.) evoked a dose-dependent, @entity1 -reversible decrease in flinching during Phase 1 and Phase 2, but @entity4 had no effect on either phase. No attenuation of the quiescent period between Phase 1 and Phase 2 was seen upon administration of @entity5 , @entity6 or @entity4 . Additionally, no increase in nocifensive behavior was observed upon administration of either GABAA or GABAB antagonists alone. Therefore, our conclusions are that both GABAA and GABAB agonists are antinociceptive at the spinal cord level and that endogenous spinal @entity3 levels are insufficient for a @entity3 potentiator to act alone in an antinociceptive manner.

title: Intrathecal XXXX and @entity6 , but not @entity4 , are antinociceptive using the rat-formalin model.

answer: @entity5


abstract: Both @entity3 ( @entity3 )A and GABAB receptor subtypes have been implicated in spinally mediated antinociception in @entity8 models. In the current study, the @entity0 test was used as a model of protracted nociception to examine the effect of intrathecally (i.t.) administered @entity5 (GABAB agonist), @entity6 (GABAA agonist) or @entity4 (a @entity2 ) on antinociception. At doses that did not affect motor function, @entity5 (0.3 and 1.0 micrograms, i.t.) decreased the flinch response in a dose-dependent manner during Phase 1 and Phase 2. This effect was reversible by the GABAB-specific antagonist, @entity7 ( @entity7 ). @entity6 (0.3 and 1.0 microgram i.t.) evoked a dose-dependent, @entity1 -reversible decrease in flinching during Phase 1 and Phase 2, but @entity4 had no effect on either phase. No attenuation of the quiescent period between Phase 1 and Phase 2 was seen upon administration of @entity5 , @entity6 or @entity4 . Additionally, no increase in nocifensive behavior was observed upon administration of either GABAA or GABAB antagonists alone. Therefore, our conclusions are that both GABAA and GABAB agonists are antinociceptive at the spinal cord level and that endogenous spinal @entity3 levels are insufficient for a @entity3 potentiator to act alone in an antinociceptive manner.

title: Intrathecal @entity5 and XXXX , but not @entity4 , are antinociceptive using the rat-formalin model.

answer: @entity6


abstract: Both @entity3 ( @entity3 )A and GABAB receptor subtypes have been implicated in spinally mediated antinociception in @entity8 models. In the current study, the @entity0 test was used as a model of protracted nociception to examine the effect of intrathecally (i.t.) administered @entity5 (GABAB agonist), @entity6 (GABAA agonist) or @entity4 (a @entity2 ) on antinociception. At doses that did not affect motor function, @entity5 (0.3 and 1.0 micrograms, i.t.) decreased the flinch response in a dose-dependent manner during Phase 1 and Phase 2. This effect was reversible by the GABAB-specific antagonist, @entity7 ( @entity7 ). @entity6 (0.3 and 1.0 microgram i.t.) evoked a dose-dependent, @entity1 -reversible decrease in flinching during Phase 1 and Phase 2, but @entity4 had no effect on either phase. No attenuation of the quiescent period between Phase 1 and Phase 2 was seen upon administration of @entity5 , @entity6 or @entity4 . Additionally, no increase in nocifensive behavior was observed upon administration of either GABAA or GABAB antagonists alone. Therefore, our conclusions are that both GABAA and GABAB agonists are antinociceptive at the spinal cord level and that endogenous spinal @entity3 levels are insufficient for a @entity3 potentiator to act alone in an antinociceptive manner.

title: Intrathecal @entity5 and @entity6 , but not XXXX , are antinociceptive using the rat-formalin model.

answer: @entity4


abstract: OBJECTIVE: China has implemented a free-service policy for @entity1 . However, @entity0 still have to pay a substantial proportion of their annual income for treatment of this disease. This study describes the economic burden on @entity0 with @entity1 ; identifies related factors by comparing two areas with different management models; and provides policy recommendation for @entity1 control reform in China. METHODS: There are three @entity1 management models in China: the @entity1 dispensary model, specialist model and integrated model. We selected Zhangjiagang (ZJG) and Taixing (TX) as the study sites, which correspond to areas implementing the integrated model and dispensary model, respectively. @entity0 diagnosed and treated for @entity1 since January 2010 were recruited as study subjects. A total of 590 @entity0 (316 @entity0 from ZJG and 274 @entity0 from TX) were interviewed with a response rate of 81%. The economic burden attributed to @entity1 , including direct costs and indirect costs, was estimated and compared between the two study sites. The Mann-Whitney U Test was used to compare the cost differences between the two groups. Potential factors related to the total out-of-pocket costs were analyzed based on a step-by-step multivariate linear regression model after the logarithmic transformation of the costs. RESULTS: The average (median, interquartile range) total cost was 18793.33 (9965, 3200-24400) CNY for @entity0 in ZJG, which was significantly higher than for @entity0 in TX (mean: 6598.33, median: 2263, interquartile range: 983-6688) (Z = 10.42, P < 0.001). After excluding expenses covered by health insurance, the average out-of-pocket costs were 14304.4 CNY in ZJG and 5639.2 CNY in TX. Based on the multivariable linear regression analysis, factors related to the total out-of-pocket costs were study site, age, number of clinical visits, residence, diagnosis delay, hospitalization, intake of liver protective drugs and use of the second-line drugs. CONCLUSION: Under the current "free of diagnosis and treatment" policy, the financial burden remains heavy on @entity1 @entity0 . Policy makers need to consider appropriate steps to lessen the burden of out-of-pocket costs for @entity1 @entity0 in China and how best to improve service delivery for poor @entity0 .

title: Is XXXX Treatment Really Free in China? A Study Comparing Two Areas with Different Management Models.

answer: @entity1


abstract: UNASSIGNED: C-peptide has intrinsic biological activity and may be renoprotective. We conducted a systematic review to determine whether C-peptide had a beneficial effect on renal outcomes. MEDLINE, EMBASE, and the Cochrane Central Databases were searched for @entity0 and animal studies in which C-peptide was administered and renal endpoints were subsequently measured. We identified 4 @entity0 trials involving 74 @entity0 as well as 18 animal studies involving 35 separate experiments with a total of 641 animals. In @entity0 , the renal effects of exogenously delivered C-peptide were only studied in type 1 diabetics with either normal renal function or incipient @entity2 . Pooled analysis showed no difference in GFR (mean difference, -1.36 mL/ @entity7 .73 m2, p = 0.72) in @entity0 receiving C-peptide compared to a control group, but two studies reported a reduction in glomerular hyperfiltration (p<0.05). Reduction in @entity4 was also reported in the C-peptide group (p<0.05). In @entity1 rodent models, C-peptide led to a reduction in GFR (mean difference, -0.62 mL/min, p<0.00001) reflecting a partial reduction in glomerular hyperfiltration. C-peptide also reduced @entity5 (mean difference, -186.25 mg/day, p = 0.05), glomerular volume (p<0.00001), and mesangial matrix area (p<0.00001) in @entity1 animals without affecting blood pressure or plasma @entity3 . Most studies were relatively short-term in duration, ranging from 1 hour to 3 months. @entity0 studies of sufficient sample size and duration are needed to determine if the beneficial effects of C-peptide seen in animal models translate into improved long-term clinical outcomes for @entity0 with @entity6 . (PROSPERO CRD42014007472).

title: C-peptide as a Therapy for XXXX : A Systematic Review and Meta-Analysis.

answer: @entity2


abstract: BACKGROUND: Bariatric surgery is currently the most efficacious treatment for @entity2 and its associated metabolic co-morbidities, such as @entity1 . The metabolic improvements occur through both weight-dependent and weight-independent mechanisms. @entity6 ( @entity8 ) have emerged as key signalling molecules that have a central role in modulating many of the physiological effects seen after bariatric surgery. This systematic review assesses the evidence from both @entity0 and animal studies for the role of @entity8 in reducing the metabolic complications of @entity2 following bariatric surgery. METHODS: We conducted a systematic search of Medline and Embase databases to identify all articles investigating the role of @entity8 in mediating the metabolic changes observed following bariatric surgery in both animal and @entity0 studies. Boolean logic was used with relevant search terms, including the following MeSH terms: ' @entity6 and salts', 'bariatric surgery', 'metabolic surgery', 'gastrointestinal tract/surgery' and ' @entity2 /surgery'. RESULTS: Following database searches (n=1197), inclusion from bibliography searches (n=2) and de-duplication (n=197), 1002 search results were returned. Of these, 132 articles were selected for full-text review, of which 38 articles were deemed relevant and included in the review. The findings support the effects of @entity8 on satiety, lipid and @entity4 metabolism, incretins and @entity5 homoeostasis, energy metabolism, gut microbiota and endoplasmic reticulum stress following bariatric surgery. Many of these metabolic effects are modulated through the BA receptors @entity7 and @entity9 . We also explore a possible link between @entity8 and @entity3 following bariatric surgery. CONCLUSIONS: Overall there is good evidence to support the role of @entity8 in the metabolic effects of bariatric surgery through the above mechanisms. @entity8 could serve as a novel therapeutic pharmacological target for the treatment of @entity2 and its associated co-morbidities.

title: The role of XXXX in reducing the metabolic complications of @entity2 after bariatric surgery: a systematic review.

answer: @entity6


abstract: BACKGROUND: Bariatric surgery is currently the most efficacious treatment for @entity2 and its associated metabolic co-morbidities, such as @entity1 . The metabolic improvements occur through both weight-dependent and weight-independent mechanisms. @entity6 ( @entity8 ) have emerged as key signalling molecules that have a central role in modulating many of the physiological effects seen after bariatric surgery. This systematic review assesses the evidence from both @entity0 and animal studies for the role of @entity8 in reducing the metabolic complications of @entity2 following bariatric surgery. METHODS: We conducted a systematic search of Medline and Embase databases to identify all articles investigating the role of @entity8 in mediating the metabolic changes observed following bariatric surgery in both animal and @entity0 studies. Boolean logic was used with relevant search terms, including the following MeSH terms: ' @entity6 and salts', 'bariatric surgery', 'metabolic surgery', 'gastrointestinal tract/surgery' and ' @entity2 /surgery'. RESULTS: Following database searches (n=1197), inclusion from bibliography searches (n=2) and de-duplication (n=197), 1002 search results were returned. Of these, 132 articles were selected for full-text review, of which 38 articles were deemed relevant and included in the review. The findings support the effects of @entity8 on satiety, lipid and @entity4 metabolism, incretins and @entity5 homoeostasis, energy metabolism, gut microbiota and endoplasmic reticulum stress following bariatric surgery. Many of these metabolic effects are modulated through the BA receptors @entity7 and @entity9 . We also explore a possible link between @entity8 and @entity3 following bariatric surgery. CONCLUSIONS: Overall there is good evidence to support the role of @entity8 in the metabolic effects of bariatric surgery through the above mechanisms. @entity8 could serve as a novel therapeutic pharmacological target for the treatment of @entity2 and its associated co-morbidities.

title: The role of @entity6 in reducing the metabolic complications of XXXX after bariatric surgery: a systematic review.

answer: @entity2


abstract: PURPOSE: Ciliary photocoagulation was used to reduce pressure in eyes with @entity2 or to suppress @entity1 . The efficiency of transscleral cyclophotocoagulation (TSCPC) with a clinical diode laser system (Iris Medical Instrument, Oculight SLX) was evaluated. METHODS: This diode laser system (wavelengh: 810 nm) provides light energy to the eye through a specially designed quartz glass fiberoptic probe allowing precise location centered 1.2 mm behind the limbus, i.e. in front of the ciliary body. Thirty eight eyes in 38 @entity0 with @entity2 underwent TSCPC with the diode laser. RESULTS: Three months after surgery, intra-ocular pressure was controlled at 20 mmHg or below in 70% of the @entity0 . @entity0 who most failed with the TSCPC had higher initial IOP (neovascular and @entity5 ). Seventy five percent of the @entity1 were painless after the laser treatment. Only a few cases (10%) of transient secondary hypertony were observed. The inflammatory response (21%) was mild and transient. No case of scleral perforation, no case of posterior @entity3 , @entity4 were observed. CONCLUSION: The transscleral ciliary photocoagulation laser diode system is efficient to reduce intraocular pressure in @entity2 . Complications are mild compared with other methods of cyclophotocoagulation. A long-term study is necessary to evaluate the results on IOP and the incidence of @entity4 .

title: [Treatment of XXXX by diode semiconductor laser cyclophotocoagulation].

answer: @entity2


abstract: OBJECTIVES: to examine the use of antithrombotic therapy and predictors of @entity1 and @entity2 in very elderly (>= 85 years) @entity3 ( @entity3 ) @entity0 in a general practice cohort from the UK. DESIGN: retrospective, observational cohort study; 12-month follow-up period. SETTING: eleven general practices serving the town of Darlington, England representing a population of 105,000 @entity0 . @entity0 : two thousand two hundred and fifty-nine @entity0 with a history of @entity3 , 561 (24.8%) aged >= 85 years. MAIN OUTCOME MEASURES: use of antithrombotic therapy by age group and predictors of @entity1 and @entity2 . RESULTS: five hundred and sixty-one (24.8%) @entity3 @entity0 aged >= 85 years (mean (SD) age 89 (4) years; 66% female) identified with a mean CHA2DS2-VASc score of 4.6 (SD 1.4). Thirty-six per cent received oral anticoagulation (OAC) compared with 57% in the 75-84 years age group. Forty-nine per cent of the very elderly received antiplatelet (AP) monotherapy; recorded OAC contraindications and declines were greatest among those aged >= 85 years. @entity1 risk was highest among the very elderly (5.2% per annum), despite anticoagulation (3.9%). Multivariate analyses demonstrated an increased risk of @entity1 with AP monotherapy (odds ratio (OR) 2.45, 95% confidence intervals (CIs) 1.05-5.70) and a significant reduction in all-cause mortality with OAC therapy (OR 0.59, 95% CI 0.36-0.99). CONCLUSION: the majority of very elderly @entity3 @entity0 in general practice do not receive OAC despite their higher @entity1 risk; almost half received AP monotherapy. AP use independently increased the risk of @entity1 , signifying that effective @entity1 prevention requires OAC regardless of age, except where true contraindications exist.

title: Impact of advanced age on management and prognosis in XXXX : insights from a population-based study in general practice.

answer: @entity3


abstract: BACKGROUND: @entity2 is a @entity7 -containing antibiotic that is effective in the treatment of several infections and for prophylaxis of @entity6 . This drug has been reported as a common culprit drug for the @entity5 ( @entity5 ) and for @entity1 ( @entity1 ). Human leukocyte antigens (HLAs) play a key role in the immunopathogenesis of severe cutaneous reactions induced by several drugs. This study investigated the association between the HLA class I and @entity4 polymorphisms and @entity2 -induced @entity5 / @entity1 in a Thai population. METHODS: Forty-three @entity0 with @entity2 -induced @entity5 / @entity1 and 91 @entity2 -tolerant @entity0 were enrolled in the study. HLA class I and @entity4 were genotyped using the reverse sequence-specific oligonucleotide probe method. RESULTS: The frequencies of three alleles of HLA, namely @entity3 *15:02, @entity8 *06:02, and @entity8 *08:01, were significantly higher in the @entity2 -induced @entity5 / @entity1 group compared with controls. The risks for @entity2 -induced @entity5 / @entity1 in @entity0 with the @entity3 *15:02, @entity8 *06:02, or @entity8 *08:01 allele were about 3-11-fold higher when compared with those who did not carry one of these alleles. Individuals who carried the @entity3 *15:02-C*08:01 haplotype had a 14-fold higher risk for @entity2 -induced @entity5 / @entity1 . CONCLUSION: Evidence of associations between @entity2 -induced @entity5 / @entity1 and HLA alleles including @entity3 *15:02, @entity8 *06:02, and @entity8 *08:01 were found in the study population. These findings may suggest that apart from the HLA molecules, other molecules involved in the molecular pathogenesis of these severe cutaneous adverse drug reactions may play an important role in the susceptibility of individuals to @entity5 / @entity1 caused by @entity2 .

title: Candidate HLA genes for prediction of XXXX -induced severe cutaneous reactions.

answer: @entity2


abstract: OBJECTIVES: Previous attempts at meta-analysis and systematic review have not provided clear recommendations for the clinical application of thermal ablation in metastatic @entity3 . Many authors believe that the probability of gathering randomised controlled trial (RCT) data is low. Our aim is to provide a consensus document making recommendations on the appropriate application of thermal ablation in @entity0 with @entity3 . METHODS: This consensus paper was discussed by an expert panel at The Interventional Oncology Sans Fronti  res 2013. A literature review was presented. Tumour characteristics, ablation technique and different clinical applications were considered and the level of consensus was documented. RESULTS: Specific recommendations are made with regard to @entity1 size, number, and location and ablation technique. Mean 31  % 5-year survival post-ablation in selected @entity0 has resulted in acceptance of this therapy for those with technically inoperable but limited @entity5 and those with limited liver reserve or co-morbidities that render them inoperable. CONCLUSIONS: In the absence of RCT data, it is our aim that this consensus document will facilitate judicious selection of the @entity0 most likely to benefit from thermal ablation and provide a unified interventional oncological perspective for the use of this technology. KEY POINTS:     Best results require due consideration of @entity2 size, number, volume and location.     Ablation technology, imaging guidance and intra-procedural imaging assessment must be optimised.     Accepted applications include @entity4 due to @entity2 distribution or inadequate liver reserve.     Other current indications include concurrent co-morbidity, @entity0 choice and the test-of-time approach.     Future applications may include resectable disease, e.g. for @entity2 .

title: Thermal ablation of XXXX : a position paper by an international panel of ablation experts, the interventional oncology sans fronti  res meeting 2013.

answer: @entity3


abstract: OBJECTIVES: To investigate  the influence of region-of-interest (ROI) placement on 3D @entity1 enhancement [Quantitative European Association for the Study of the Liver (qEASL)] in @entity2 ( @entity2 ) @entity0 treated with transcatheter arterial chemoembolization (TACE). METHODS: Phase 1: 40 @entity2 @entity0 had nine ROIs placed by one reader using systematic techniques (3 ipsilateral to the lesion, 3 contralateral to the lesion, and 3 dispersed throughout the liver) and qEASL variance was measured. Intra-class correlations were computed. Phase 2: 15 @entity2 @entity0 with histosegmentation were selected. Six ROIs were systematically placed by AC (3 ROIs ipsilateral and 3 ROIs contralateral to the lesion). Three ROIs were placed by 2 radiologists. qEASL values were compared to histopathology by @entity3 , linear regression, and median difference. RESULTS: Phase 1: The dispersed method (abandoned in phase 2) had low consistency and high variance. Phase 2: qEASL correlated strongly with pathology in systematic methods [ @entity3 coefficient   =   0.886 (ipsilateral) and 0.727 (contralateral)] and in clinical methods (0.625 and 0.879). However, ipsilateral placement matched best with pathology (median difference: 5.4  %; correlation: 0.89; regression CI: [0.904, 0.1409]). CONCLUSIONS: qEASL is a robust method with comparable values among tested placements. Ipsilateral placement showed high consistency and better pathological correlation. KEY POINTS:     Ipsilateral and contralateral ROI placement produces high consistency and low variance.     Both ROI placement methods produce qEASL values that correlate well with histopathology.     Ipsilateral ROI placement produces best correlation to pathology along with high consistency.

title: Radiologic-pathologic analysis of quantitative 3D XXXX enhancement on contrast-enhanced MR imaging: a study of ROI placement.

answer: @entity1


abstract: BACKGROUND: This study aimed to develop a simple method of creating an animal model of non-trauma @entity2 using African ostriches with weights similar to those of @entity0 . METHODS: Eighteen African ostriches were subjected to liquid nitrogen cryo-insult in the unilateral femoral head through surgical procedures using homemade cryogenic equipment combined with tract drilling inside the femoral head. Three animals were sacrificed at postoperative weeks 6 and 12, respectively, and the remaining animals were sacrificed at postoperative week 24. Bilateral femoral heads were harvested and subjected to gross observation, histological examination using hematoxylin and eosin staining, and radiographic examination. Micro-computed tomography was performed on a portion of the specimens at postoperative week 24, and angiographic examination of the femoral head was performed before sacrificing the animals. RESULTS: Eight ostriches developed a limp at postoperative week 8, with a mean duration of 16.5  weeks. The postoperative femoral head specimens showed changes in contour and articular cartilage degeneration. Sagittal sectioning of the collapsed femoral head specimens revealed distinct boundaries among the osteonecrotic areas, @entity3 , and normal trabeculae. Histological examinations revealed active bone resorption in the osteonecrotic area of the subchondral bone, an increased number of fat cells, and active trabecular bone regeneration in the @entity3 . The postoperative radiographic examinations revealed that the height of the femoral head gradually decreased and progressed to collapse. Micro-computed tomography scans showed the interrupted trabecular bone with an irregular shape in the collapsed femoral head. Compared with the normal samples, angiographic findings revealed interrupted blood supply of the cryo-injured samples in some areas of the femoral heads, blood vessel narrowing, and decreased number of blood vessels in the cryo-injured areas. CONCLUSION: This study indicates that an animal model of @entity2 progressing to collapse can be established via a simplified method of cryosurgery. This model possesses histological features that are similar to those of @entity0 ; thus, it can be used as an ideal animal model for the study of femoral @entity1 .

title: A simple method for establishing an ostrich model of XXXX .

answer: @entity2


abstract: PURPOSE: This article reports the outcome of free temporalis fascia and muscle graft ( @entity4 ) reconstruction of the @entity3 ( @entity3 ) with and without simultaneous orthognathic surgery (SOS). MATERIALS AND METHODS: Twenty-nine @entity0 (45 joints) were evaluated retrospectively. Group 1 consisted of 17 @entity0 (16 @entity0 1 @entity0 ) and 30 joints. Fifteen (88%) @entity0 had sagittal split ramus osteotomies (SSRO); 8 (53%) of these @entity0 also had Le @entity2 , and 2 @entity0 (12%) had only Le @entity2 with @entity4 . Group 2 consisted of 12 @entity0 (15 joints) who received only @entity4 and no SOS. RESULTS: Group 1 had 9 @entity0 (53%) with an incisal opening greater than 35 mm, 11 joints (37%) with greater than 6 mm lateral excursive movement, and 11 @entity0 (65%) were asymptomatic postoperatively. Average follow-up was 57.4 months (range, 23 to 69 months). Group 2 had eight @entity0 (67%) with an incisal opening greater than 35 mm, six joints (40%) with greater than 6 mm lateral excursive movement, and seven @entity0 (58%) were asymptomatic postoperatively. Average follow-up was 55.1 months (range, 48 to 64 months). CONCLUSION: @entity4 with and without SOS produced similar treatment outcomes in comparing groups 1 and 2. No significant differences were observed for the number of @entity0 with an incisal opening > 35 mm (P = .703), lateral excursion > 6 mm (P = 1.00), and successful elimination of @entity1 (P = 1.00), even though group 2 had a significantly greater number of @entity0 (P < 0.01) that were operated on unilaterally. Combining treatment outcomes for both groups, the number of previous joint surgeries significantly affected success (P < .01). The presence of osteoarthritic changes did-not significantly affect treatment outcome (P = .187).

title: Reconstruction of the XXXX using a temporalis graft with or without simultaneous orthognathic surgery.

answer: @entity3


abstract: BACKGROUND: It is unknown whether the symptoms of first and recurrent @entity5 ( @entity5 ) are similar in the same @entity0 . This study examined the frequency of symptom mismatch, which factors are associated with a symptom mismatch and how symptom mismatch is related to 28-day case fatality. DESIGN: Observational study. METHODS: The sample consisted of 1282 @entity0 with a first and recurrent @entity5 , recruited from a population-based @entity5 registry, 1985-2011. Occurrence of 11 symptoms was recorded in first and recurrent @entity5 using standardized @entity0 interview. Logistic regression modelling adjusted for demographic and clinical variables was applied. RESULTS: Mismatch was highest for dyspnoea (40.6%) and lowest for chest symptoms (10.4%). Compared with @entity0 , @entity0 were less likely to have a mismatch of @entity2 between the shoulder blades (odds ratio (OR) 0.58, 95% confidence interval (CI) 0.43-0.79), @entity2 in the throat/jaw (OR 0.67, 95% CI 0.50-0.91), @entity3 (OR 0.62, 95% CI 0.47-0.82), @entity4 (OR 0.50, 95% CI 0.36-0.71), or fear of death (OR 0.71, 95% CI 0.53-0.94), or to have three or more mismatching symptoms (OR 0.60, 95% CI 0.45-0.79). @entity0 with @entity1 were more likely to have a mismatch in chest symptoms, whereas @entity0 with hyperlipidaemia or @entity0 who received any revascularization therapy at first @entity6 were significantly less likely to have a mismatch of chest symptoms. Twenty-eight-day case fatality significantly increased with the number of mismatching symptoms (OR 1.14, 95% CI 1.02-1.28). CONCLUSIONS: @entity0 with @entity5 may benefit from information about the possibility that a recurrent @entity6 may be associated with different symptoms.

title: Mismatch of presenting symptoms at first and recurrent XXXX . From the MONICA/KORA Myocardial Infarction Registry.

answer: @entity5


abstract: INTRODUCTION: @entity6 , an oral multikinase inhibitor, is the only targeted agent approved for the treatment of @entity0 with @entity2 ( @entity2 ) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in @entity2 and Of its treatment with @entity6 ) is the largest, global, non-interventional, prospective study of @entity0 with uHCC (n>3200) treated with @entity6 in real-life clinical practice conditions. Here we report the final analysis of safety and efficacy in the Italian cohort of @entity0 . METHODS: @entity0 with unresectable @entity2 who are candidates for systemic therapy, and for whom a decision has been made to treat with @entity6 , are eligible for inclusion. @entity0 demographics disease characteristics and treatment history were recorded at baseline visit. @entity6 dose, concomitant medications, performance status, liver function, adverse events and efficacy (survival and response rate) were collected throughout the study. RESULTS: In the Italian cohort of the GIDEON study 278 @entity0 were included in 36 centers. The global rate of adverse events was 81%. Drug-related events accounted for 67%, mostly of grade 1 and 2, and only 8% were classified as serious. The most common were @entity3 (24%), @entity4 (23%), dermatological (14%), @entity5 /exfoliation (10%), @entity1 (9%), hemorrage/bleeding of gastrointestinal tract (6%). Overall survival was 14.4 months and time to progression 6.2 months. Objective responses were observed in 14 @entity0 (5%) with 3 complete responses (1%). Stable diseases of at least 6 weeks were observed in 113 @entity0 (41%) with a 30% of disease control rate. DISCUSSION: The safety profile of @entity6 in terms of rate and type of adverse events is similar to that emerged in the global international GIDEON study as well as in the pivotal registration studies.

title: [Therapeutic decisions and treatment with XXXX in @entity2 : final analysis of GIDEON study in Italy].

answer: @entity6


abstract: INTRODUCTION: @entity6 , an oral multikinase inhibitor, is the only targeted agent approved for the treatment of @entity0 with @entity2 ( @entity2 ) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in @entity2 and Of its treatment with @entity6 ) is the largest, global, non-interventional, prospective study of @entity0 with uHCC (n>3200) treated with @entity6 in real-life clinical practice conditions. Here we report the final analysis of safety and efficacy in the Italian cohort of @entity0 . METHODS: @entity0 with unresectable @entity2 who are candidates for systemic therapy, and for whom a decision has been made to treat with @entity6 , are eligible for inclusion. @entity0 demographics disease characteristics and treatment history were recorded at baseline visit. @entity6 dose, concomitant medications, performance status, liver function, adverse events and efficacy (survival and response rate) were collected throughout the study. RESULTS: In the Italian cohort of the GIDEON study 278 @entity0 were included in 36 centers. The global rate of adverse events was 81%. Drug-related events accounted for 67%, mostly of grade 1 and 2, and only 8% were classified as serious. The most common were @entity3 (24%), @entity4 (23%), dermatological (14%), @entity5 /exfoliation (10%), @entity1 (9%), hemorrage/bleeding of gastrointestinal tract (6%). Overall survival was 14.4 months and time to progression 6.2 months. Objective responses were observed in 14 @entity0 (5%) with 3 complete responses (1%). Stable diseases of at least 6 weeks were observed in 113 @entity0 (41%) with a 30% of disease control rate. DISCUSSION: The safety profile of @entity6 in terms of rate and type of adverse events is similar to that emerged in the global international GIDEON study as well as in the pivotal registration studies.

title: [Therapeutic decisions and treatment with @entity6 in XXXX : final analysis of GIDEON study in Italy].

answer: @entity2


abstract: OBJECTIVE: To describe our experience with @entity8 ( @entity8 )-associated @entity9 and @entity2 , and to assess treatment strategies. STUDY DESIGN: We reviewed hospital charts and autopsy reports of all University of Minnesota @entity0 with @entity8 between 1975 and August 1994. We identified six @entity0 with colonopathy and compared them with a cohort of 79 @entity0 with @entity8 in the same age range and seen during the same period. RESULTS: All @entity0 with colonopathy had bloody @entity3 ; five of the six had @entity5 . Stool frequency and related symptoms distinguished the @entity0 with colonopathy from the cohort population. All took a higher median dose of pancreatic enzymes than the cohort population during the 3 months preceding the onset of symptoms (p < 0.002). For all six @entity0 , barium studies revealed loss of haustration, and shortening and diffuse narrowing of the colonic lumen with relative rectal sparing. The distal ileal mucosa was irregular in four @entity0 . A histopathologic study reveal @entity1 , and focal acute cryptitis in all six @entity0 . Other features included @entity6 (2/6) and nodular regenerative @entity7 of the liver (1/6). One @entity0 continues to have symptoms, three had subtotal colectomy, and the condition of two improved after a regimen including a low-fat diet, withholding of pancreatic enzymes, and supplemental parenteral nutrition was initiated. CONCLUSIONS: @entity2 represents a newly recognized @entity4 of @entity8 . Affected @entity0 have taken larger doses of pancreatic enzymes than similar @entity0 with @entity8 , and have bloody @entity3 . We developed a medical protocol that may avoid surgical resection of the colon in some of these @entity0 .

title: @entity8 and XXXX .

answer: @entity2


abstract: OBJECTIVE: To describe our experience with @entity8 ( @entity8 )-associated @entity9 and @entity2 , and to assess treatment strategies. STUDY DESIGN: We reviewed hospital charts and autopsy reports of all University of Minnesota @entity0 with @entity8 between 1975 and August 1994. We identified six @entity0 with colonopathy and compared them with a cohort of 79 @entity0 with @entity8 in the same age range and seen during the same period. RESULTS: All @entity0 with colonopathy had bloody @entity3 ; five of the six had @entity5 . Stool frequency and related symptoms distinguished the @entity0 with colonopathy from the cohort population. All took a higher median dose of pancreatic enzymes than the cohort population during the 3 months preceding the onset of symptoms (p < 0.002). For all six @entity0 , barium studies revealed loss of haustration, and shortening and diffuse narrowing of the colonic lumen with relative rectal sparing. The distal ileal mucosa was irregular in four @entity0 . A histopathologic study reveal @entity1 , and focal acute cryptitis in all six @entity0 . Other features included @entity6 (2/6) and nodular regenerative @entity7 of the liver (1/6). One @entity0 continues to have symptoms, three had subtotal colectomy, and the condition of two improved after a regimen including a low-fat diet, withholding of pancreatic enzymes, and supplemental parenteral nutrition was initiated. CONCLUSIONS: @entity2 represents a newly recognized @entity4 of @entity8 . Affected @entity0 have taken larger doses of pancreatic enzymes than similar @entity0 with @entity8 , and have bloody @entity3 . We developed a medical protocol that may avoid surgical resection of the colon in some of these @entity0 .

title: XXXX and @entity2 .

answer: @entity8


abstract: INTRODUCTION: Although there are approximately 1.1 million case presentations of mild @entity1 (mTBI) in the @entity4 ( @entity4 ) each year, little data is available to clinicians to identify @entity0 who are at risk for poor outcomes, including 72-hour @entity4 return after discharge. An understanding of @entity0 at risk for @entity4 during the hyperacute phase following @entity5 would allow @entity4 providers to develop clinical interventions that reduce its occurrence and improve outcomes. METHODS: This institutional review board-approved consecutive cohort study collected injury and outcome variables on adults with the purpose of identifying positive predictors for 72-hour @entity4 in mTBI @entity0 . RESULTS: Of 2,787 mTBI @entity0 , 145 (5%) returned unexpectedly to the @entity4 within 72 hours of hospital discharge. Positive predictors for @entity4 included being male (p=0.0298), being black (p=0.0456), having a lower prehospital Glasgow @entity6 Score (p=0.0335), suffering the injury due to a motor vehicle collision (p=0.0065), or having a bleed on head computed tomography (CT) (p=0.0334). @entity4 were not significantly associated with age, @entity3 on head CT, or symptomology following @entity5 . @entity0 with return visits most commonly reported post-concussion syndrome (43.1%), @entity2 (18.7%), and recall for further clinical evaluation (14.6%) as the reason for return. Of the 124 @entity0 who returned to the @entity4 within 72 hours, one out of five were admitted to the hospital for further care, with five requiring intensive care unit stays and four undergoing neurosurgery. CONCLUSION: Approximately 5% of adult @entity0 who present to the @entity4 for mTBI will return within 72 hours of discharge for further care. Clinicians should identify at-risk individuals during their initial visits and attempt to provide anticipatory guidance when possible.

title: Understanding Why @entity0 Return to the Emergency Department after Mild XXXX .

answer: @entity1


abstract: INTRODUCTION: Although there are approximately 1.1 million case presentations of mild @entity1 (mTBI) in the @entity4 ( @entity4 ) each year, little data is available to clinicians to identify @entity0 who are at risk for poor outcomes, including 72-hour @entity4 return after discharge. An understanding of @entity0 at risk for @entity4 during the hyperacute phase following @entity5 would allow @entity4 providers to develop clinical interventions that reduce its occurrence and improve outcomes. METHODS: This institutional review board-approved consecutive cohort study collected injury and outcome variables on adults with the purpose of identifying positive predictors for 72-hour @entity4 in mTBI @entity0 . RESULTS: Of 2,787 mTBI @entity0 , 145 (5%) returned unexpectedly to the @entity4 within 72 hours of hospital discharge. Positive predictors for @entity4 included being male (p=0.0298), being black (p=0.0456), having a lower prehospital Glasgow @entity6 Score (p=0.0335), suffering the injury due to a motor vehicle collision (p=0.0065), or having a bleed on head computed tomography (CT) (p=0.0334). @entity4 were not significantly associated with age, @entity3 on head CT, or symptomology following @entity5 . @entity0 with return visits most commonly reported post-concussion syndrome (43.1%), @entity2 (18.7%), and recall for further clinical evaluation (14.6%) as the reason for return. Of the 124 @entity0 who returned to the @entity4 within 72 hours, one out of five were admitted to the hospital for further care, with five requiring intensive care unit stays and four undergoing neurosurgery. CONCLUSION: Approximately 5% of adult @entity0 who present to the @entity4 for mTBI will return within 72 hours of discharge for further care. Clinicians should identify at-risk individuals during their initial visits and attempt to provide anticipatory guidance when possible.

title: Understanding Why XXXX Return to the Emergency Department after Mild @entity1 .

answer: @entity0


abstract: Deficiencies in DNA repair due to inherited germ-line mutations in DNA repair genes cause increased risk of @entity2 . In @entity2 , mutations in DNA repair genes are relatively rare. However, epigenetic alterations that reduce expression of DNA repair genes are frequent in @entity2 . These epigenetic reductions are also found in field defects that give rise to @entity1 . Reduced DNA repair likely allows excessive DNA damages to accumulate in somatic cells. Then either inaccurate translesion synthesis past the un-repaired DNA damages or error-prone DNA repair can cause mutations. Erroneous DNA repair can also cause epigenetic alterations (i.e., epimutations, transmitted through multiple replication cycles). Some of these mutations and epimutations may cause progression to @entity1 . Thus, deficient or absent DNA repair is likely an important underlying cause of @entity1 . Whole genome sequencing of @entity2 show that between thousands to hundreds of thousands of mutations occur in these @entity1 . Epimutations that reduce DNA repair gene expression and occur early in progression to @entity2 are a likely source of this high genomic instability. @entity1 cells deficient in DNA repair are more vulnerable than normal cells to inactivation by DNA damaging agents. Thus, some of the most clinically effective chemotherapeutic agents in @entity1 treatment are DNA damaging agents, and their effectiveness often depends on @entity3 in @entity1 cells. Recently, at least 18 DNA repair proteins, each active in one of six DNA repair pathways, were found to be subject to epigenetic reduction of expression in @entity2 . Different DNA repair pathways repair different types of DNA damage. Evaluation of which DNA repair pathway(s) are @entity2 and/or particular @entity0 may prove useful in guiding choice of therapeutic agents in @entity1 therapy.

title: Epigenetic reduction of DNA repair in progression to XXXX .

answer: @entity2


abstract: INTRODUCTION: Laser phototherapy is used for the treatment of chemotherapy-induced @entity7 in @entity0 with @entity4 , although there are limited data supporting the safety of this method. This study aimed to evaluate the effect of different doses of low-level laser on proliferation of @entity6 ( @entity6 ) cell line (KG-1a) in vitro. METHODS: A plastic flask containing 5,000,000 KG-1a cultured cells was provided by Iran Pasteur Institute. KG-1a cell line has been produced from the bone marrow aspirate of a 59-year-old white male with @entity6 . Upon completion of the proliferation steps of KG-1a cell line, 7*10(4) cells were placed in 96-well tissue culture plates. All the surrounding wells were filled with Wright-Giemsa stain in order to prevent laser from scattering to the neighboring wells. In total, 28 plates were prepared using this method. After a forty-eight hours incubation period, irradiation was performed in continuous mode with an infrared laser of 810nm wavelength. After 24 hours, cells cultures were exposed to one, two, or three applications of laser irradiation. Irradiation exposures were performed at energy densities of 5, 10, and 20 J/cm(2) . Each experiment included 18 replicates for each application of laser and 6 replicates of negative/untreated controls. For experiments with two and three repeated exposures, the irradiation applications were separated by 48 hours. All the culture plates were incubated for seven days. Cell proliferation was evaluated using the @entity3 ( @entity5 ) assay after seven days. Spectroscopy (620nm) was used to determine the optical density (OD) of both irradiated and control samples. RESULTS: Significant increase in cell proliferation was seen only after two exposures at energy density of 20J/cm2 (P=0.021). CONCLUSION: Although LLLT is commonly used to treat radiotherapy- or chemotherapy- induced @entity2 , as long as further studies demonstrate that different wavelengths and doses of laser phototherapy are safe and effective in treatment of @entity2 , clinicians should remain cautious regarding the use of this treatment modality to treat @entity0 with @entity1 .

title: The effect of low-level laser therapy on XXXX leukemic cells.

answer: @entity0


abstract: BACKGROUND: Preclinical testing of potential therapies for @entity3 ( @entity3 ) is conducted predominantly of the mdx @entity0 . But lack of a detailed quantitative description of the pathology of this animal limits our ability to evaluate the effectiveness of putative therapies or their relevance to @entity3 . METHODS: Accordingly, we have measured the main cellular components of muscle growth and regeneration over the period of postnatal growth and early pathology in mdx and @entity2 ( @entity2 ) @entity0 ; @entity5 binding is used as a measure of fibre size, myonuclear counts and @entity4 labelling as records of myogenic activity. RESULTS: We confirm a two-phase postnatal growth pattern in @entity2 muscle: first, increase in myonuclear number over weeks 1 to 3, then expansion of myonuclear domain. Mdx muscle growth lags behind that of @entity2 prior to overt signs of pathology. Fibres are smaller, with fewer myonuclei and smaller myonuclear domains. Moreover, satellite cells are more readily detached from mdx than @entity2 muscle fibres. At 3  weeks, mdx muscles enter a phase of florid myonecrosis, accompanied by concurrent regeneration of an intensity that results in complete replacement of pre-existing muscle over the succeeding 3 to 4  weeks. Both @entity2 and mdx muscles attain maximum size by 12 to 14  weeks, mdx muscle fibres being up to 50% larger than those of @entity2 as they become increasingly branched. Mdx muscle fibres also become hypernucleated, containing twice as many myonuclei per sarcoplasmic volume, as those of @entity2 , the excess corresponding to the number of centrally placed myonuclei. CONCLUSIONS: The best-known consequence of lack of dystrophin that is common to @entity3 and the mdx @entity0 is the conspicuous @entity1 and regeneration of muscle fibres. We present protocols for measuring this in terms both of loss of muscle nuclei previously labelled with @entity4 and of the intensity of myonuclear labelling with @entity4 administered during the regeneration period. Both measurements can be used to assess the efficacy of putative antinecrotic agents. We also show that lack of dystrophin is associated with a number of previously unsuspected abnormalities of muscle fibre structure and function that do not appear to be directly associated with myonecrosis.

title: Muscular dystrophy in the mdx XXXX is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia.

answer: @entity0